Mesoblast Stock Leads 3 Fast Growing ASX Picks With Strong Insider Ownership

Simply Wall St.08-23

Global purchasing manager surveys point to resilient services activity even as some manufacturing data stays mixed. That kind of steady demand can be helpful for fast growing companies where insiders ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2661624340?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-23 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661624340","market":"nz","top_or_hot":-1,"title":"Mesoblast Stock Leads 3 Fast Growing ASX Picks With Strong Insider Ownership","media":"Simply Wall St.","content":"<div>\n<p>Global purchasing manager surveys point to resilient services activity even as some manufacturing data stays mixed. That kind of steady demand can be helpful for fast growing companies where insiders ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-stock-leads-3-fast-growing-asx-picks-with-strong-i\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Stock Leads 3 Fast Growing ASX Picks With Strong Insider Ownership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Stock Leads 3 Fast Growing ASX Picks With Strong Insider Ownership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-23 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-stock-leads-3-fast-growing-asx-picks-with-strong-i><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Global purchasing manager surveys point to resilient services activity even as some manufacturing data stays mixed. That kind of steady demand can be helpful for fast growing companies where insiders ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-stock-leads-3-fast-growing-asx-picks-with-strong-i\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX","symbol_name":"Telix Pharmaceuticals Ltd. (Uplisting)","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-stock-leads-3-fast-growing-asx-picks-with-strong-i","article_id":"2661624340","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-stock-leads-3-fast-growing-asx-picks-with-strong-i","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661624340","pubTimestamp":1787494952,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Global purchasing manager surveys point to resilient services activity even as some manufacturing data stays mixed. That kind of steady demand can be helpful for fast growing companies where insiders already hold a meaningful stake. When managers and founders keep skin in the game, their interests are closely tied to yours. This article highlights three stocks from the Fast Growing Stocks With High Insider Ownership screener that fit that profile.\nThe three stocks below are only a starting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","LIN.AU":"LINDIAN RESOURCES LTD","BK4139":"生物科技","BK7067":"生物科技","MESO":"Mesoblast Limited","BK7095":"多种金属与采矿","MSB.AU":"MESOBLAST LTD","TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7501":"新冠治疗股","BK7508":"医药生物股"},"translate_title":"Mesoblast 股票以强大的内部所有权引领 3 只快速增长的 ASX 精选股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX":0.73,"MESO":1.5,"LIN.AU":1,"MSB.AU":1,"TLX.AU":1},"content_text":"Global purchasing manager surveys point to resilient services activity even as some manufacturing data stays mixed. That kind of steady demand can be helpful for fast growing companies where insiders already hold a meaningful stake. When managers and founders keep skin in the game, their interests are closely tied to yours. This article highlights three stocks from the Fast Growing Stocks With High Insider Ownership screener that fit that profile. The three stocks below are only a starting sample from this idea, and the full screen surfaced 99 more companies where growth, insider ownership and forward looking expectations create similarly compelling narratives not covered here. If you want to go straight to the source and size up this opportunity set for yourself, use the Fast Growing Stocks With High Insider Ownership screener to identify, filter and analyze the candidates that best match your own conviction. AdvertisementMesoblast (ASX:MSB) Overview: Mesoblast is a Melbourne based biotech that develops regenerative cell therapies, built around mesenchymal lineage cells, to treat severe inflammatory and cardiovascular conditions such as steroid refractory acute graft versus host disease, inflammatory bowel disease, chronic low back pain and chronic heart failure. Its late stage Remestemcel L and MPC programs are central to why Mesoblast features in a screener focused on fast growing companies where management and analysts share an optimistic view of the pipeline’s commercial potential. Operations: Mesoblast currently generates about $65 million from the development of its cell technology platform for commercialization. Market Cap: A$3.1b Mesoblast gives you exposure to a late stage regenerative medicine story in which multiple Phase III programs in conditions like steroid refractory acute graft versus host disease, inflammatory bowel disease and chronic low back pain are all converging at once. Analysts are projecting very strong improvements in revenue and earnings if these therapies progress, which helps explain why the stock features in a screener built around high growth expectations and committed insiders. At the same time, Mesoblast is still unprofitable and relies on external funding, so delays, regulatory setbacks or weaker than hoped uptake for Ryoncil and rexlemestrocel L could affect both cash needs and sentiment. For investors who can tolerate clinical and financing risk, that combination of ambition and uncertainty is what makes Mesoblast a candidate for closer examination. Mesoblast’s late stage pipeline and insider alignment hint at a story that could be moving faster than the market credits. Tap into the analyst forecasts for Mesoblast to see what expectations might be missing. ASX:MSB Earnings & Revenue Growth as at Aug 2026 Build your own fast growth and insider alignment shortlist Mesoblast and the other two stocks in this list were all surfaced through a single screener, but the real value comes when you create filters that match your own growth, insider ownership and risk preferences. Use our customisable Screener to mix metrics like valuation, future growth, balance sheet strength and risk flags, or lean on any of our curated Investing Ideas. Telix Pharmaceuticals (ASX:TLX) Overview: Telix Pharmaceuticals develops and commercialises radiopharmaceutical drugs that help doctors precisely image and treat cancers, with a particular focus on prostate, kidney and brain tumours through products such as TLX591 and diagnostic agents like Illuccix and BiPASS. These products are central to its high growth, precision medicine story. Operations: Telix generates about US$705 million from Precision Medicine and US$277 million from Manufacturing Solutions. Smaller segment adjustments and eliminations reflect intra group activity. Market Cap: A$5.3b Telix Pharmaceuticals gives you direct exposure to precision oncology. Illuccix, Gozellix and the BiPASS pathway already support a sizeable imaging business, while late stage programs such as TLX591 in advanced prostate cancer and TLX250 in kidney cancer aim to convert that diagnostic footprint into higher value therapies. Recent updates show revenue growth around 22% and guidance for more than US$1b in 2026 sales. However, that ambition comes with notable tension points including rich expectations on growth, heavy R&D spend and reliance on debt funding. The FDA feedback on certain imaging products and the SEC subpoena highlight that clinical, regulatory and disclosure risks are live issues, which is exactly why many investors keep Telix on their watchlist rather than in the too hard basket. Telix Pharmaceuticals is building a billion dollar precision oncology platform, yet many investors still treat it as a niche imaging story. Use the analyst forecasts for Telix Pharmaceuticals and see how current expectations handle the FDA and SEC overhangs. ASX:TLX Earnings & Revenue Growth as at Aug 2026 Lindian Resources (ASX:LIN) Overview: Lindian Resources is a Perth based explorer focused on the Kangankunde Rare Earths project in Malawi, a flagship deposit aimed at supplying rare earth elements used in clean energy and high tech applications, alongside earlier stage gold and bauxite interests in Africa and Australia. The rare earths focus is the clearest link to the fast growth and insider alignment theme, while the broader exploration portfolio provides additional optionality rather than the main driver. Market Cap: A$1.4b Lindian Resources may appeal to investors seeking direct exposure to a rare earths story that is tied to a specific asset and timeline. Kangankunde is being advanced toward first monazite concentrate production in Q4 2026 with ore already being mined and stockpiled. The company is still loss making, has relied on dilution and higher risk funding, and carries governance questions with a young, less independent board. That balance of potential and execution risk places the focus on how effectively Lindian can convert a promising project into sustainable, less diluted cash flows. Lindian Resources is racing to turn Kangankunde into cash flow, while funding needs and board questions still hang in the background. Get a clearer read on that balance through the analysis report for Lindian Resources ASX:LIN Earnings & Revenue Growth as at Aug 2026 Seeking Fresh Alternatives Before They Fly Fresh ideas do not stay under the radar for long. Breakout stories build momentum while others get caught dropping from view. Scan these curated lists before the crowd and consider your options.  Spot companies turning stable cash and strong balance sheets into quiet momentum by running a focused search across the list of solid balance sheet and fundamentals (21 results). Explore potential upside in hard assets by reviewing the hand picked producers inside the 32 elite gold producer stocks. Identify structural growth themes early by checking the curated mix of infrastructure enablers in the 55 AI infrastructure stocks.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Telix Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661624340","isCrawlerRequest":true}